Login to Your Account



Search

Search results

Clinic roundup

Cellceutix Corp. , of Beverly, Mass., said the seventh cohort is under way in the phase I trial of anticancer drug candidate, Kevetrin, dosing 165 mg/m2 of Kevetrin compared to 110 mg/m2 in the prior cohort. (BioWorld-Today-2014-03-20) ...

BioWorld Today - Staff - 2014-03-19 23:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Novo Nordisk A/S , of Bagsvaerd, Denmark, reported positive results from pathfinder2, the first phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients. (BioWorld-Today-2014-03-20) ...

BioWorld Today - Staff - 2014-03-19 23:00 - 0 comments - 0 attachments

Clinic roundup

Alcobra Ltd. , of Tel Aviv, Israel, said the first patient has been enrolled in a phase III trial of metadoxine extended release (MDX) in the treatment of adults with attention deficit hyperactivity disorder (ADHD). (BioWorld-Today-2014-03-1 ...

BioWorld Today - Staff - 2014-03-18 23:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Ipsen SA , of Paris, reported phase IIa results showing that Dysport was associated with a mean reduction from baseline of urinary incontinence episodes greater than 75 percent, 12 weeks after injection, regardless of how the drug was administered in ...

BioWorld Today - Staff - 2014-03-18 23:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Astrazeneca plc , of London, (AZN) said patient enrollment was completed approximately four months ahead of plan in the phase III trial EUCLID studying Brilinta (ticagrelor) tablets. (BioWorld-Today-2014-03-18) ...

BioWorld Today - Staff - 2014-03-17 23:00 - 0 comments - 0 attachments

Clinic roundup

Edison Pharmaceuticals Inc. , of Mountain View, Calif., said it started a phase II trial, titled “A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone) in Children with Pearson Syndrome,” designed as a subject-controlled study lasting 12 month ...

BioWorld Today - Staff - 2014-03-17 23:00 - 0 comments - 0 attachments

Clinic roundup

Achillion Pharmaceuticals Inc. , of New Haven, Conn., said presentations at the Asian Pacific Association for the Study of the Liver in Brisbane, Australia, included updated phase II results evaluating a 150-mg loading dose following by 50 mg once da ...

BioWorld Today - Staff - 2014-03-16 23:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Glaxosmithkline plc (GSK), of London, said a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reducing the frequency of exacerbations in patients with severe eosinophilic ast ...

BioWorld Today - Staff - 2014-03-13 23:00 - 0 comments - 0 attachments

Clinic roundup

Idera Pharmaceuticals Inc. , of Cambridge, Mass., said it plans to start clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomysitis, two orphan autoimmune diseases. ...

BioWorld Today - Staff - 2014-03-13 23:00 - 0 comments - 0 attachments

Clinic roundup

Senesco Technologies Inc. , of Bridgewater, N.J., opened two sites in the Republic of South Africa in its open-label, multiple-dose, dose-escalation phase Ib/IIa study of SNS01-T, which is evaluating the safety and tolerability in 15 patients wit ...

BioWorld Today - Staff - 2014-03-12 23:00 - 0 comments - 0 attachments